International Journal of Hematology

, Volume 73, Issue 4, pp 411–415 | Cite as

Clonality in the Myelodysplastic Syndromes

  • Jacqueline Boultwood
  • James S. Wainscoat
Progress in hematology


The myelodysplastic syndromes (MDSs) comprise a heterogeneous group of stem cell disorders involving cytopenia and dysplastic changes in 3 hematopoietic lineages. Although it is accepted that MDS is a clonal disorder, the exact nature of the involvement of multipotent stem cells and progenitor cells has not been resolved. Most clonality studies of MDS support the proposal that the primary neoplastic event occurs, in most patients, at the level of a committed myeloid progenitor cell, capable of differentiation into multiple myeloid lineages. The extent of the involvement of T and B lymphocytes in MDS remains controversial. Much of the variation reported may result from disease heterogeneity and technical issues such as skewed methylation patterns occurring in studies analyzing X-chromosome inactivation patterns (XCIP) and possible impurities in lymphocyte preparation. A great deal of the evidence in support of T-lymphocyte involvement in MDS has been generated by XCIP studies, and some of these data need to be treated with caution, especially data from studies in which appropriate controls were omitted. In contrast, B-lymphocyte involvement in some patients with MDS is based on studies using more robust technology including combined immunophenotyping and fluorescence in situ hybridization. Clonality studies involving myeloid and lymphoid cells in MDS have yielded discrepant results with regard to the potential involvement of multipotent (lympho-myeloid) hematopoietic stem cells (HSCs). However, failure to detect a clonal marker in all cells of all lineages does not preclude multipotent-HSC involvement. Some recent studies have produced compelling evidence to show that, in some patients with MDS, the multipotent HSC is the target of the primary neoplastic event. It now seems probable that MDS arises in multipotent HSCs more commonly than previously recognized. Such data not only provide important new insights into the biology of MDS but also may have therapeutic implications. The determination of whether multipotent HSCs are involved in the MDS clone may be important for the use of autologous stem cell transplantation in these patients.

Key words

Myelodysplastic syndromes Multipotent hematopoietic stem cell Clonality X-chromosome inactivation patterns Fluorescence in situ hybridization 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes.Leuk Lymphoma. 1995;16:247–262.CrossRefPubMedGoogle Scholar
  2. 2.
    Heaney ML, Gold DW. Myelodysplasia.N Engl J Med. 1999;340:1649–1660.CrossRefPubMedGoogle Scholar
  3. 3.
    Heim S, Mitelman F. Chromosome abnormalities in the myelodys-plastic syndromes.Clin Haematol. 1986;15:1003–1021.PubMedGoogle Scholar
  4. 4.
    Nowell PC. Chromosome abnormalities in myelodysplastic syndromes.Semin Oncol. 1992;19:189–194.Google Scholar
  5. 5.
    Yunis JJ, Lobell M, Arnesen MA, et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndromes and acute myelogenous leukaemia.Br J Haematol. 1988;68:189–194.CrossRefPubMedGoogle Scholar
  6. 6.
    Weimar IS, Bourhis JH, de Gast GC, Gerritsen WR. Clonality in myelodysplastic syndromes.Leuk Lymphoma. 1994;13:215–221.CrossRefPubMedGoogle Scholar
  7. 7.
    Gale RE. Evaluation of clonality in myeloid stem-cell disorders.Semin Hematol. 1999;36:361–372.PubMedGoogle Scholar
  8. 8.
    Gale RE, Wainscoat JS. Clonal analysis using X-linked DNA polymorphisms.Br J Haematol. 1993;85:2–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Kibbelarr RE, van Kamp H, Dreef EJ, et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes.Blood. 1992;79:1823–1828.Google Scholar
  10. 10.
    Van Lom K, Hagemeijer A, Smit EME, Löenberg B. In situ hybridization on May-Grünewald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allow detection of cell-lineage-specific cytogenetic abnormalities.Blood. 1993;82:884–888.PubMedGoogle Scholar
  11. 11.
    Han K, Lee W, Harris CP, Kim W, Shim S, Meisner LF. Quantifying chromosome changes and lineage involvement in myelodysplastic syndrome (MDS) using fluorescent in situ hyridization (FISH).Leukemia. 1994;8:81–86.PubMedGoogle Scholar
  12. 12.
    Varmus HE, Lowell CA. Cancer genes and hematopoiesis.Blood. 1994;83:5–9.PubMedGoogle Scholar
  13. 13.
    Jandl JH.Blood: Textbook of Haematology, 2nd ed. Boston, MA: Little, Brown; 1996.Google Scholar
  14. 14.
    Shinohara T, Takuwa N, Morishita K, et al. Chronic myelomono-cytic leukaemia with a chromosome abnormality (46,XY,20q-) in all dividing myeloid cells: evidence for clonal origin in a multipotent stem cell common to granulocyte, monocyte, erythrocyte, and thrombocyte.Am J Hematol. 1983;15:289–293.CrossRefPubMedGoogle Scholar
  15. 15.
    Abrahamson G, Boultwood J, Madden J, et al. Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses.Br J Haematol. 1991;79:550–555.CrossRefPubMedGoogle Scholar
  16. 16.
    Van Lom K, Hagemeijer A, Smith EME, Haehlem K, Groeneveld K, Loewenberg B. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineages.Leukemia. 1995;9:1818–1821.PubMedGoogle Scholar
  17. 17.
    Kroef MJ, Fibe WE, Mout R, et al. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions.Blood. 1993;18:1849–1854.Google Scholar
  18. 18.
    Kroef MJ, Bolk MJ, Muus P, et al. Mosaicism of the 5q deletion as assessed by interphase FISH is a common phenomenon in MDS and restricted to myeloid cells.Leukemia. 1997;11:519–523.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    White NJ, Nacheva E, Asimakopoulos FA, Bloxham D, Paul B, Green AR. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells.Blood. 1994;83:2809–2816.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ. Evidence of a multistep pathogenesis of a myelodysplastic syndrome.Blood. 1984;63:1318–1323.PubMedGoogle Scholar
  21. 21.
    Jaju RJ, Jones M, Boultwood J, et al. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.Genes Chromosomes Cancer. 2000;29:276–280.CrossRefPubMedGoogle Scholar
  22. 22.
    Gerritsen WR, Donohue J, Bauman J, et al. Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization.Blood. 1992;80:217–224.PubMedGoogle Scholar
  23. 23.
    Saitoh K, Miura I, Takahashi N, Miura AB. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes.Blood. 1998;92:2886–2892.PubMedGoogle Scholar
  24. 24.
    Parlier V, Tiainen M, Beris P, Miescher PA, Knuutila S, Jotterand-Bellomo M. Trisomy 8 detection in granulomonocytic, erythrocytic and megakaryocytic lineages by chromosomal in situ suppression hybridization in a case of refractory anaemia with ringed siderob-lasts complicating the course of paroxysmal nocturnal haemoglo-binuria.Br J Haematol. 1992;81:296–304.CrossRefPubMedGoogle Scholar
  25. 25.
    Knuutila S. Lineage specificity in haematological neoplasms.Br J Haematol. 1997;96:2–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Janssen, JW, Buschie, M, Layton, M, et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.Blood. 1989;73:248–254.PubMedGoogle Scholar
  27. 27.
    Preudhomme C, Vachee A, Morschauser G, Henic N, Cosson A, Fenaux P. Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase.Leuk Res. 1994;18:365–371.CrossRefPubMedGoogle Scholar
  28. 28.
    Wainscoat JS, Fey MF, Pilkington S, Summers C, Oscier DG. Absence of immunoglobulin and T-cell receptor gene rearrangements in myelodysplastic syndromes and acute nonlympocytic leukemias.Am J Hematol. 1988;28:95–97.CrossRefPubMedGoogle Scholar
  29. 29.
    Fialkow PJ. Use of genetic markers to study cellular origin of development of tumors in human females.Adv Cancer Res. 1972;15:191–226.CrossRefPubMedGoogle Scholar
  30. 30.
    Tsukamoto N, Morita K, Maehara T, et al. Clonality in myelodys-plastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms.Br J Haematol. 1993:83:589–594.CrossRefPubMedGoogle Scholar
  31. 31.
    Tefferi A, Thibodeau SN, Solberg LA Jr. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphism.Blood. 1990;75:1770–1773.PubMedGoogle Scholar
  32. 32.
    Van Kamp H, Fibbe WE, Jansen RP, et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene.Blood. 1992;80:1774–1780.PubMedGoogle Scholar
  33. 33.
    Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.Blood. 1996;88:59–65.PubMedGoogle Scholar
  34. 34.
    Champion KM, Gilbert JGR, Asimakopoulos FA, Hinshelwood S, Green AR. Clonal haematopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes.Br J Haematol. 1997;97:920–926.CrossRefPubMedGoogle Scholar
  35. 35.
    Gale RE, Fielding AK, Harrison CN, Linch DC. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggest stochastic clonal loss with age.Br J Haematol. 1997;95:512–519.CrossRefGoogle Scholar
  36. 36.
    Billstrom R, Johansson B, Strombeck B, et al. Clonal CD5-positive B lymphocytes in myelodysplastic syndrome with systemic vasculitis and trisomy 8.Ann Hematol. 1997;74:37–40.CrossRefPubMedGoogle Scholar
  37. 37.
    Nilsson L, Astrand-Grundström I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.Blood. 2000;96:2012–2021.PubMedGoogle Scholar
  38. 38.
    Kouides A, Bennett JM. Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: case report and review of the literature of lymphoblastic transformation of myelodysplastic syndrome.Am J Hematol. 1995;49:157–162.CrossRefPubMedGoogle Scholar
  39. 39.
    Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA. Clonal lymphocytes are detectable in only some cases of MDS.Br J Haematol. 1992;81:346–352.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Miura I, Kobayashi Y, Takahashi N, Saitoh K, Muira AB. Short report: involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting.Br J Haematol. 2000;110:876–879.CrossRefPubMedGoogle Scholar
  41. 41.
    Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.Blood. 1998;92:4758–4763.PubMedGoogle Scholar
  42. 42.
    Galy A, Travis M, Cen D, Chen B, Human T. B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset.Immunity. 1995;3:459–473.CrossRefPubMedGoogle Scholar
  43. 43.
    Buckton KE, Brown WM, Smith PG. Lymphocyte survival in men treated with x-rays for ankylosing spondylitis.Nature. 1967;214:470–473.CrossRefPubMedGoogle Scholar
  44. 44.
    Busque L, Kohler S, De Hart D, et al. High incidence of polyclonal granulocytopoiesis in myelodysplastic syndromes (MDS) [abstract].Blood. 1993;82(suppl 1):196a.Google Scholar
  45. 45.
    Bernell, P, Jacobsson, B, Nordgren, A, Hast, R. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.Leukemia. 1996;10:662–668.PubMedGoogle Scholar
  46. 46.
    Asano H, Ohasi H, Ichihara M, et al. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes.Blood. 1994;84:588–594.PubMedGoogle Scholar
  47. 47.
    Delforge M, Demuynck H, Vandenbergh EP, et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes.Blood. 1995;86:3660–3667.PubMedGoogle Scholar
  48. 48.
    Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.Br J Haematol. 1997;99:939–944.CrossRefPubMedGoogle Scholar
  49. 49.
    De Witte T, Van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS.Blood. 1997;90:3853–3857.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  1. 1.Leukaemia Research Fund Molecular Haematology UnitNuffield Department of Clinical Laboratory Sciences, John Radcliffe HospitalOxfordUK

Personalised recommendations